Researchers Halt Trial of Promising Sickle Cell Treatment
NY Times
FEBRUARY 22, 2021
Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible.
Clinical Trials DNA Genetic Engineering 
54 
The Importance of Hazard Communications in Clinical Trials Involving Genetic Engineering
Advarra
JUNE 13, 2024
Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. How can I protect myself from exposure? What should I do if I’m exposed?
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Leading innovators in gene splicing using nucleases for the pharmaceutical industry
Pharmaceutical Technology
FEBRUARY 15, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.
A history of blood cancer treatment
pharmaphorum
SEPTEMBER 13, 2022
Although clinical trials proved that chemicals could be used to treat cancer, the results of the study remained a closely guarded military secret until 1946. This was an entirely new approach to DNA research. Previously, DNA would be segmented into short sections, which would then be read and sequenced separately.
Gene Switch: A Novel Platform for Switching Genes On and Off
Roots Analysis
AUGUST 31, 2023
Gene switches can be regulatory proteins or specific DNA sequences that act to either switch on or off the expression of a gene. Basic Components of Gene Switch Gene switches are composed of noncoding DNA sequences and transcription factors.
Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval
Advarra
AUGUST 10, 2023
However, recent advancements in the clinical use of recombinant DNA (rDNA) technology creates opportunities for changing this calculation and addressing a great, unmet medical need. “I Keep in mind, there is no cost to register an IBC with the NIH. Research sites without access to an IBC may consider relying on a commercial IBC.
Risk Assessment for use of Engineered Genetic Materials in Clinical Research
Advarra
MARCH 31, 2023
The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Either way, occupational exposure to these gene delivery systems bears potential risks to the research staff.
Let's personalize your content